The accessible portion of the STAT article places this story in the context of the Inflation Reduction Act (IRA) of 2022, which authorized a limited federal program for Medicare to negotiate prices on selected high-cost medicines. The IRA was enacted in response to concerns about rising prescription drug costs and created a process under which the Centers for Medicare and Medicaid Services (CMS) can conduct rounds of negotiations with drug manufacturers for certain drugs covered by Medicare.
CMS has been preparing subsequent rounds of negotiations with drugmakers under that statutory framework. The STAT excerpt makes clear that the timing of CMS’s administrative choices matters for when particular medicines become eligible for negotiation under the IRA process.
According to an analysis by the consumer advocacy group Public Citizen, a relatively obscure change in Medicare policy led to a seven-year delay before a blockbuster AbbVie drug became subject to price negotiations. Public Citizen argues that this delay was consequential and that it shifted financial burdens onto taxpayers. The STAT excerpt attributes the seven-year figure to Public Citizen’s analysis.
The accessible text does not reproduce the analysis itself (for example, the underlying timeline, statutory interpretation, or data sources Public Citizen used). STAT’s piece identifies Public Citizen as the source of the claim but does not include the detailed evidence or methodology in the publicly visible portion of the article.
The article states that the Medicare policy change occurred as CMS was preparing a new round of talks with drugmakers. It characterizes the decision as “little-noticed,” indicating limited public awareness or disclosure at the time the policy shift was made. The accessible excerpt does not specify the administrative mechanism used by CMS, the regulatory language that was changed, or the exact timing and dates of the policy action.
Because the STAT story beyond the excerpt is available only to STAT+ subscribers, the excerpt does not provide the name of the specific AbbVie medicine affected, the statutory or regulatory provision CMS altered, or the sequence of events that produced the alleged seven-year extension.
Public Citizen’s central claim, as described in the STAT excerpt, is that the seven-year postponement of a drug’s eligibility for negotiation would likely harm taxpayers by delaying federal price reductions that could otherwise have lowered Medicare spending. The article frames the change as coming "at the expense of taxpayers."
The STAT excerpt does not include numerical estimates of the fiscal impact, such as projected additional Medicare spending, patient out-of-pocket costs, or anticipated savings had the drug been subject to negotiations earlier. Those quantitative details — if they exist — are not present in the accessible portion of the report.
The publicly available portion of the STAT story establishes several facts: that Public Citizen conducted an analysis, that the group concluded a Medicare policy change produced a seven-year delay for an AbbVie drug’s entry into the IRA negotiation process, and that the change took place while CMS was preparing another negotiation round. The excerpt also emphasizes that this reporting is a STAT+ exclusive.
Important specifics are not included in the accessible excerpt. The following items are not reported in the visible text of the article and therefore cannot be confirmed from the source provided here:
The STAT excerpt explicitly indicates that readers must subscribe to STAT+ to access the remainder of the story, which likely contains further detail and sourcing.
The accessible reporting raises questions about administrative transparency and oversight when agencies make decisions that affect drug-pricing timelines under the IRA. Public Citizen’s analysis, as summarized by STAT, suggests that seemingly technical or minor policy choices can have significant fiscal consequences.
Because the accessible source text omits key details needed to fully evaluate the claim, readers seeking to verify the analysis, review CMS’s rationale, or examine any quantified fiscal impacts will need access to the remainder of the STAT article or to the Public Citizen report itself. The excerpt highlights the need for additional reporting or official documentation to clarify the mechanism of the delay and to provide empirical estimates of its cost or benefit.
Conclusion
The STAT excerpt reports that Public Citizen identified a Medicare policy change that it believes produced a seven-year postponement of price negotiations for a high-revenue AbbVie medicine under the Inflation Reduction Act framework. The accessible text confirms the core allegation but does not provide the detailed evidence, timelines, fiscal estimates, or responses from CMS or AbbVie. Those details were not reported in the publicly available portion of the article and would be necessary to independently assess the claim’s magnitude and policy significance.